Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):e247-e250. doi: 10.1016/j.clml.2019.03.001. Epub 2019 Mar 11.

Authors

Daniel R Reed¹, Richard D Hall², Ryan D Gentzler², Leonid Volodin², Michael G Douvas², Craig A Portell²

Affiliations

¹ Division of Hematology/Oncology, University of Virginia, Charlottesville, VA. Electronic address: [email protected].
² Division of Hematology/Oncology, University of Virginia, Charlottesville, VA.

PMID: 30992232
DOI: 10.1016/j.clml.2019.03.001

No abstract available

Keywords: Cytogenics; Non-Hodgkin lymphoma; Peripheral T cell lymphoma; Targeted therapy; Treatment toxicity.

Publication types

Case Reports

MeSH terms

Adult
Anaplastic Lymphoma Kinase / antagonists & inhibitors
Anaplastic Lymphoma Kinase / genetics*
Biomarkers
Carbazoles / administration & dosage
Carbazoles / adverse effects
Carbazoles / therapeutic use*
Drug Resistance, Neoplasm / genetics*
Gene Rearrangement*
Humans
Lymphoma, Large-Cell, Anaplastic / diagnosis
Lymphoma, Large-Cell, Anaplastic / drug therapy*
Lymphoma, Large-Cell, Anaplastic / genetics*
Lymphoma, Large-Cell, Anaplastic / mortality
Male
Molecular Targeted Therapy
Piperidines / administration & dosage
Piperidines / adverse effects
Piperidines / therapeutic use*
Positron Emission Tomography Computed Tomography
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Retreatment
Tomography, X-Ray Computed
Treatment Outcome

Substances

Biomarkers
Carbazoles
Piperidines
Protein Kinase Inhibitors
ALK protein, human
Anaplastic Lymphoma Kinase
alectinib